Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOM3355 phase IIb study in Huntington's disease with chorea
2021-003453-28Phase 2Active
- Sponsor
- SOM Biotech
- Start
- Dec 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bevantolol in Huntington disease (HD) (3 arms), sponsored by SOM Biotech. Primary endpoint: Change in Total Maximal Chorea sub-score of the Unified Huntington's Disease Rating Scale. Started Dec 2021; status: active.
02
Drugs
bevantolol
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2021-003453-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003453-28.